Sibutramin in obesity treatment (multicentric, opened, prospective 12-month-long study);Sibutramín v liečbe obezity (multicentrická, otvorená, prospektívna 12-mesačná štúdia)

Vnitrni Lekarstvi

Volumn 50, Issue 11, 2004, Pages 825-829

  Payer, Juraj ^a,e   Hainer, V ^b   Ondrejka, P ^c   Kajtor, Z ^d  

^a FNsP ^*  (Slovakia)

^b INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^c Nemocnica s Poliklinikou   (Slovakia)

^d ABBOTT LABORATORIES   (United States)

^e Interne Oddelenie FNsP Ruzinov   (Slovakia)

Author keywords

Obesity; Sibutramin; Weight reduction

Indexed keywords

SIBUTRAMINE; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; DIET THERAPY; DRUG EFFECT; DRUG MECHANISM; ENERGY METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; OBESITY; OPEN STUDY; PHYSICAL ACTIVITY; SATIETY; SIDE EFFECT; WEIGHT REDUCTION; MIDDLE AGED;

APPETITE DEPRESSANTS; CYCLOBUTANES; FEMALE; HUMANS; MIDDLE AGED; OBESITY;

EID: 9444243898     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. World Health Organisation, Controlling the Global Obesity Epidemic, July 24, 2002. Dostupné: www.who.int/nut/obs.html
2. Manson, J. E., Willet, W. C., Stampfer, M. J.: Body weight and mortality among women. N. Eng. J. Med. 333, 1996, 677 - 685
3. Colditz, G. A., Willett, W. C., Rotniczky, A. et al.: Weight gain as risk factor for clinical diabetes mellitus in women. Ann. Int. Med. 122, 1995, 481 - 486
4. Hainer, V., Kunešová, M. et al.: Obezita. 1.vyd. Galén, Praha, 1997, 16
5. Avdičová, J.: Program CINDI Banská Bystrica. Zdravotnícke noviny 6, 2002, 5
6. Tuomilehto, J., Lindstrom, J., Eriksson, J. G. et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New. Engl. J. Med. 344, 2001; 1343 - 1350
7. Knowler, W. C., Barrett-Connor, E., Fowler, S. E. et al. and the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 2002; 393 - 403
8. Williamson, D. F., Pamuk, E., Thun, M. et al.: prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40 - 64 years. Am. J. Epidemiol. 141, 1995; 1128 - 1141
9. International Obesity Task Force: www.obesite.chaire.ulaval.ca/iotf.htm
10. Colditz, G. A.: Economic cost of obesity. Am. J. Clin. Nutr. 55, 1992, 5035 - 5075
11. Cole, J. O., Levin, A., Beake, B. et al.: Sibutramine: a new weight loss without evidence of the abuse potential associated with amphetamines. J. Clin. Psychopharmacol. 18, 1998, 231 - 236
12. Hainer, V., Kunešová, M., Bellisle, F. et al. & STO Study Group: Psychobehavioral and nutritional predictors of weight loss in obese patients treated with sibutramine. Submitted to Int. J. Obes.
13. Astrup, A., Chong, E.: Weight loss produced by sibutramine: a meta-analysis. Int. J. Obes. Relat. Metab. Disord. 23, 2001, 104
14. James, W. P., Astrup, A., Finer, N. et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet, 306, 2000, 2119 - 2125
15. Apfelbaum, M., Vagne, P., Ziegler, O. et al.: Long term maintenance of weight loss after a very-low calorie diet: a randomized blinded trial of efficacy and tolerability of sibutramine. Am. J. Med., 106, 1999, 179 - 184
16. Finer, N., Bloom, S. R., Frost, G. S. et al.: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes, Obesity, Metabolism, 2, 2000, 2, 105 - 112
17. Vozár, J., Waszcuk, P., Záhoráková, A. et al.: Sibutramín v liečbe obezity u diabetikov 2. typu. Diabetes a obezita, 1, 2001, 2, 44 - 51
18. Hazenberg, B. P.: Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology, 94, 2000, 152 - 158
19. McMahon, R. G., Fujioka, K., Singh, B. N. et al.: Efficacy and safety of sibutramine in obese white and african american patients with hypertension. Arch. Intern. Med. 160, 2000, 2185 - 2190